Phase II Study of BI 2536 in Prostate Cancer
NCT00706498
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostatic Neoplasms
Interventions
DRUG:
BI 2536
Sponsor
Boehringer Ingelheim